Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
Diamant Thaçi(University of Lübeck), Marius Ardeleanu(Regeneron (United States)), Thomas Bieber(CK-CARE), Makoto Kawashima(Tokyo Women's Medical University), Margitta Worm(Charité - Universitätsmedizin Berlin), Neil M.H. Graham(UK Dementia Research Institute), Jacek C. Szepietowski(Wroclaw Medical University), Howard Sofen(VA Sepulveda Ambulatory Care Center), Andrew Blauvelt(Veterans Health Administration), Lisa A. Beck(Newcastle University), Weily Soong(Allergy, Asthma and Clinical Research Center), Neil Stahl(Arthritis and Rheumatism Associates), Ariel Teper(Insmed (United Kingdom)), George D. Yancopoulos(Regeneron (United States)), Gianluca Pirozzi(Sanofi (United States)), Eric L. Simpson(Oregon Health & Science University), Steven P. Weinstein(Regeneron (United States)), E. Rand Sutherland(Sanofi (United States)), Vera Mastey(Regeneron (United States)), Richard Wu(Regeneron (United States)), Kim Papp(University of Toronto)
Cited by 566
Related Papers
Vascular-specific growth factors and blood vessel formation
|Nature|2000|3.7k
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
|New England Journal of Medicine|2018|1.9k
VEGF-Trap: A VEGF blocker with potent antitumor effects
|Proceedings of the National Academy of Sciences|2002|1.7k